Fully Automated Scan Technique Optimisation of Scan Timing in Chest CT ([FAST-START])

March 19, 2019 updated by: Joachim Wildberger, Maastricht University Medical Center

Computed Tomography Angiography (CTA) is a non-invasive imaging tool widely used for various indications. Contrast media (CM) is used to enhance the intravascular lumen and organ parenchyma, depending on the indication. Recent technical advances in CT scan techniques allow for a very fast scan acquisition with substantially increased image quality in terms of temporal and spatial resolution. However, with faster scan acquisition, challenges arise with regard to CM bolus timing. The risk of outrunning the CM bolus in these fast acquisitions is higher, resulting in a decreased intravascular attenuation and subsequent hypothetical increase in non-diagnostic image quality.

Previous studies have investigated the reduction of CM volume. When reducing the CM volume, the total injection time decreases and the window of peak enhancement shortens and becomes more narrow. The latter increases when injecting small CM volumes with higher flow rates. Although the peak enhancement increases, the window of peak enhancement decreases more rapidly. Thus, when administered with the same flow rate, the peak of the enhancement curve will be lower, narrower and faster compared to larger CM volumes. This, in combination with the faster scan acquisition makes the timing of the start of the scan highly important, since scanning at the peak enhancement is necessary to achieve a diagnostic image quality.

New bolus tracking auto-delay software (Fully Automated Scan Technique, FAST, Siemens Healthineers) automatically estimates the delay needed to scan at the peak of the enhancement curve. With help of this software, the optimal individual scan delay and enhancement can be achieved, and the risk of non-diagnostic scans should decrease. Therefore, this study aims to evaluate the performance of the Bolus Tracking Auto-Delay (FAST) software in patients receiving a standard chest CT with regard to the number of non-diagnostic scans (< 300 HU) and compare this with standard care (manual set pre-scan delay).

Study Overview

Detailed Description

Computed Tomography Angiography (CTA) is a non-invasive imaging tool widely used for various indications. Contrast media (CM) is used to enhance the intravascular lumen and organ parenchyma, depending on the indication. Recent technical advances in CT scan techniques allow for a very fast scan acquisition with substantially increased image quality in terms of temporal and spatial resolution. These faster scan times account for a significant reduction in radiation dose, which is desirable in light of the "As Low As Reasonably Achievable" (ALARA) principle. Another advantage of the newer 'high-end' scanners is the use of lower tube voltages and lower CM volumes, since many studies have shown that CM volumes can be reduced with usage of lower tube voltages.

However, with faster scan acquisition, challenges arise with regard to CM bolus timing. The risk of outrunning the CM bolus in these fast acquisitions is higher, subsequently leading to a decreased or even non-diagnostic enhancement (in Hounsfield Units (HU)). In addition, decreased CM volumes due to usage of lower tube voltages also add to the risk of outrunning the bolus. When reducing the CM bolus, the injection time decreases and the window of peak enhancement is shorter and more narrow. Also, when injecting these smaller CM volumes at higher flow rates, although the peak enhancement is increased, the window of peak enhancement decreases more rapidly. Thus, when administered with the same flow rate, the peak of the enhancement curve will be lower, narrower and faster compared to larger CM volumes. This, in combination with the faster scan acquisition makes the timing of the start of the scan (scan start delay) highly important, since scanning at the peak enhancement is necessary to achieve a diagnostic image quality.

To determine scan delay, two techniques frequently used in daily clinical routine are the 'test bolus' and 'bolus tracking' technique. With the first, a smaller CM bolus is administered before the actual scan, and the time to peak of the intravascular enhancement is determined with help of dedicated software (DynEva, Siemens Healthineers, Forchheim, Germany). When using the 'bolus tracking' technique, no additional CM volume is administered. A region of interest (ROI) is placed in a large artery of interest (e.g. ascending or descending aorta), and a threshold enhancement is set prior to the scan (e.g. 100 HU). Repetitive low dose scans are acquired at the same level and the arrival of the CM bolus is followed. Once the threshold is reached, the scanner automatically starts the scan. Between reaching the threshold and the actual start of the scan, a manual post-tracking delay is set prior to scanning. This delay is necessary for both the table movement of the scanner to the start of the scan and the breath hold command. The problem is that this manual post-tracking delay is set prior to the scan, without information of the patient's cardiovascular dynamics (e.g. cardiac output). Since cardiac output can vary greatly inter- and intra-patient, this fixed post-tracking delay may not be appropriate for all patients. Scanning with a sub-optimal post tracking delay could potentially result in suboptimal arterial enhancement and insufficient diagnostic quality.

With new bolus tracking auto-delay software (Fully Automated Scan Technique, FAST, Siemens Healthineers) the incidence of scans made at a suboptimal attenuation could be reduced. This software is similar to the 'bolus tracking' technique, the difference is that the manual post-tracking delay is calculated automatically by the software. During the low-dose repetitive scans at the level of the ROI, the attenuation in the ROI is used to predict the optimal enhancement curve. The software takes the injection protocol, tube voltage and patient parameters into account. A previously acquired database of numerous enhancement curves is consulted to predict a best fitted enhancement curve of the individual patient. The software then calculates the optimal post-tracking scan delay to scan at the peak enhancement. Thus, the optimal individual scan delay and enhancement based on the patients physiology can be achieved, and the risk of non-diagnostic scans should decrease. Therefore, this study aims to evaluate the performance of the FAST software in patients receiving standard chest CT with regard to the number of non-diagnostic scans (< 300 HU) and compare this with standard care (manual set pre-scan delay).

Study Type

Interventional

Enrollment (Actual)

223

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Limburg
      • Maastricht, Limburg, Netherlands, 6202 AZ
        • Maastricht University Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients referred for standard chest CT
  • Patients older than 18 years and competent to give informed consent

Exclusion Criteria:

  • Hemodynamic instability;
  • Pregnancy;
  • Renal insufficiency (defined as Glomerular Filtration Rate (GFR) < 30 mL/min (Odin protocol 004720));
  • Iodine allergy;
  • Age <18 years;
  • Absence of informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: FAST software
Patient referred for chest CT and scanned with delay based on bolus tracking with FAST software. intervention: FAST START Software delay
Scan delay will be determined by the FAST software bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold the FAST START software calculates the delay.
Active Comparator: Control
Patient referred for chest CT and scanned with delay based on bolus tracking without FAST software. Intervention: Manual bolus tracking delay
Scan delay will be determined by the standard bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold a delay of 6 s is chosen (table movement and breath hold command) and the scan starts.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intravascular enhancement
Time Frame: 2 years
To evaluate the performance of the FAST software in patients receiving a thoracic CTA with regard to the number of non-diagnostic scans (< 300 HU) in comparison with standard care (manual scan delay).
2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Enhancement curves
Time Frame: 2 years
To assess the enhancement curves calculated by the FAST software with regards to scan timing and delay and compare it with the scan timing and delay of the control group.
2 years
Intravascular attenuation
Time Frame: 2 years
To assess the objective image quality with regard to intravascular attenuation in patients receiving standard CTA of the thorax with the FAST software.
2 years
Image noise
Time Frame: 2 years
To assess the objective image quality with regard to image noise in patients receiving standard CTA of the thorax with the FAST software.
2 years
Signal-to-noise
Time Frame: 2 years
To assess the objective image quality with regard to signal-to-noise in patients receiving standard CTA of the thorax with the FAST software.
2 years
Contrast-to-noise
Time Frame: 2 years
To assess the objective image quality with regard to contrast-to-noise in patients receiving standard CTA of the thorax with the FAST software.
2 years
Subjective image quality
Time Frame: 2 years

To assess the subjective (Likert scale) image quality parameters in patients receiving standard CTA of the thorax with the FAST software. a 4-point Likert scale will be used:

  • 4: Excellent, absence of any image-degrading artefacts related to breathing or noise;
  • 3: Good, presence of few minor image-degrading artefacts related to breathing or noise;
  • 2: Moderate, presence of some image-degrading artefacts related to breathing or noise, with influence on image and diagnostic quality;
  • 1: Poor, presence of image-degrading artefacts related to breathing or noise with severe influence on image and diagnostic quality.
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Joachim E Wildberger, Prof., Maastricht University Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 5, 2018

Primary Completion (Actual)

December 31, 2018

Study Completion (Actual)

December 31, 2018

Study Registration Dates

First Submitted

April 25, 2018

First Submitted That Met QC Criteria

September 3, 2018

First Posted (Actual)

September 5, 2018

Study Record Updates

Last Update Posted (Actual)

March 21, 2019

Last Update Submitted That Met QC Criteria

March 19, 2019

Last Verified

March 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NL63106.068.17

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pulmonary Disease

Clinical Trials on FAST start software delay

3
Subscribe